Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ATT
Abattis Bioceuticals
C$0.00
C$0.05
C$0.74
N/AN/A1.42 million shsN/A
(TAM) stock logo
TAM
(TAM)
$0.00
$18.95
$26.96
N/AN/A330,661 shsN/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ATT
Abattis Bioceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ATT
Abattis Bioceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
(TAM) stock logo
TAM
(TAM)
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ATT
Abattis Bioceuticals
0.00
N/AN/AN/A
(TAM) stock logo
TAM
(TAM)
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ATT
Abattis Bioceuticals
N/AN/AN/AN/AN/AN/A
(TAM) stock logo
TAM
(TAM)
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ATT
Abattis Bioceuticals
N/AN/A0.00N/AN/AN/AN/AN/AN/A
(TAM) stock logo
TAM
(TAM)
N/AN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ATT
Abattis Bioceuticals
N/AN/AN/AN/AN/A
(TAM) stock logo
TAM
(TAM)
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
ATT
Abattis Bioceuticals
N/A
(TAM) stock logo
TAM
(TAM)
N/A

Insider Ownership

CompanyInsider Ownership
ATT
Abattis Bioceuticals
N/A
(TAM) stock logo
TAM
(TAM)
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
ATT
Abattis Bioceuticals
N/AN/AN/ANot Optionable
(TAM) stock logo
TAM
(TAM)
N/AN/AN/ANot Optionable

Recent News About These Companies

Nvidia stock target boosted at Citi on expanded AI TAM
Atlassian: If It Drops 10%, It Could Be A Strong Value Play
ICC WTC Final 2025 sees 75% ad volume drop despite record viewership: TAM adex

Top Headlines

View All Headlines

Abattis Bioceuticals CNSX:ATT

Abattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.

(TAM) stock logo

(TAM) NYSE:TAM

Taminco Corp is a producer of alkylamines and alkylamine derivatives. The Company's products are used by its customers in the manufacturing of everyday products primarily for the agriculture, water treatment, personal and home care, animal nutrition and oil and gas end-markets. It operates in 19 countries with seven production facilities and, as of December 31, 2012, had an installed production capacity of 1,272 thousand tons. The Company has three business segments: Functional Amines, Specialty Amines, and Crop Protection. In March 2014, the Company announced that it completed the acquisition of the formic acid business of Kemira Oyj. Its main shareholder is Eastman Chemical Company.